The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.
 
Kevin Joseph Harrington
Honoraria - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst); Vyriad (Inst)
Consulting or Advisory Role - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD (Inst); Oncolys BioPharma (Inst); Replimune (Inst); Vyriad (Inst)
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Replimune (Inst)
 
Anthony Kong
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Amgen; Centauri Therapeutics; MSD; Puma Biotechnology
Speakers' Bureau - Bristol-Myers Squibb; Merck; MSD
Research Funding - AstraZeneca (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - Merck; MSD
 
Nicolas Mach
Stock and Other Ownership Interests - MaxiVax
Patents, Royalties, Other Intellectual Property - Geneva University; MaxiVax
 
Jason Alan Chesney
Research Funding - Amgen; Bristol-Myers Squibb; Iovance Biotherapeutics; Replimune
Patents, Royalties, Other Intellectual Property - University of Louisville US Patents
 
Beatriz Castelo
No Relationships to Disclose
 
Danny Rischin
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Kura Oncology (Inst); Merck (Inst); Merck KGaA (Inst); Regeneron (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Merck
(OPTIONAL) Uncompensated Relationships - GlaxoSmithKline; Merck; Regeneron; Sanofi
 
Ezra E.W. Cohen
Consulting or Advisory Role - Bayer; BioNTech; Eisai; Gilead Sciences; Merck; MSD; Regeneron
 
Hoi-Shen Radcliffe
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Burak Gumuscu
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Wendy Snyder
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Janpix; Loxo; Merck; Mirati Therapeutics; MorphoSys; Navire; Oncorus; Relay Therapeutics; Roche; Seagen; Symphogen; Treadwell Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)